Five things for pharma marketers to know: Monday, November 30, 2020
AstraZeneca COVID-19 vaccine requires more data; 40 million coronavirus vaccines expected to be produced by end of year; New cases top 200,000 in the U.S. on Friday.
AstraZeneca COVID-19 vaccine requires more data; 40 million coronavirus vaccines expected to be produced by end of year; New cases top 200,000 in the U.S. on Friday.
Regeneron’s experimental coronavirus treatment receives emergency use approval; Pfizer/BioNTech request emergency use approval for COVID-19 vaccine; Vaccine could be distributed as soon as 24-hours after receiving approval.
HHS pilot program brings rapid, POC coronavirus tests to five states; CDC: Americans should not travel for Thanksgiving; J&J makes a $100 million diversity pledge.
FDA to approve Moderna, Pfizer COVID-19 vaccines for emergency use as quickly as possible; Moderna’s coronavirus vaccine is 94.5% effective; 65 WHO employees have contracted the virus.
Biden’s COVID-19 task force to meet with drugmakers; More than 68,500 hospitalized with coronavirus on Friday; MM+M 40 Under 40 nominations are open.
Six out of ten American will not get COVID-19 vaccine unless it reduces risk by 50%; FDA approves Lilly’s coronavirus antibody treatment; Obamacare unlikely to be struck down.
President-elect Joe Biden to name coronavirus task force team; Biogen’s Alzheimer’s drug receives thumbs-down from FDA advisory panel; MM+M Holiday Contest entries are open.
More than 100,000 COVID-19 cases in U.S. in a single day; Regeneron’s coronavirus antibody treatment up for potential emergency use authorization; Biogen’s Alzheimer’s drug to receive FDA approval.
White House memo warns of “deadly phase” for COVID pandemic; False positives occurring with rapid coronavirus antigen test; Omada Health’s diabetes prevention platform shows promising results.
NY to require visitors to get COVID-19 tested; Britain begins accelerated review for AstraZeneca coronavirus vaccine; Crispr may cause unwanted side effects in human embryo cells.